Search Result

Results for "

AChE/BChE Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (1) Amyloid-β (5) Apoptosis (2) Beta-secretase (7) Calcium Channel (1) Cannabinoid Receptor (1) Carbonic Anhydrase (2) CDK (1) Cholinesterase (ChE) (89) COX (1) Endogenous Metabolite (1) Glucosidase (3) GSK-3 (1) Histamine Receptor (1) Histone Acetyltransferase (1) iGluR (2) Isotope-Labeled Compounds (4) Mitochondrial Metabolism (1) MMP (1) Monoamine Oxidase (14) NOD-like Receptor (NLR) (1) Parasite (1) Phosphodiesterase (PDE) (1) Reactive Oxygen Species (5) ROS Kinase (3) Tau Protein (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (4) Metabolic Disease (6) Neurological Disease (80)

By Targets:

Amylases (1)

Amyloid-β (5)

Apoptosis (2)

Beta-secretase (7)

Calcium Channel (1)

Cannabinoid Receptor (1)

Carbonic Anhydrase (2)

CDK (1)

Cholinesterase (ChE) (89)

COX (1)

Endogenous Metabolite (1)

Glucosidase (3)

GSK-3 (1)

Histamine Receptor (1)

Histone Acetyltransferase (1)

iGluR (2)

Isotope-Labeled Compounds (4)

Mitochondrial Metabolism (1)

MMP (1)

Monoamine Oxidase (14)

NOD-like Receptor (NLR) (1)

Parasite (1)

Phosphodiesterase (PDE) (1)

Reactive Oxygen Species (5)

ROS Kinase (3)

Tau Protein (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (4)

Metabolic Disease (6)

Neurological Disease (80)

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-161311

AChE/BChE-IN-18	Cholinesterase (ChE) Cannabinoid Receptor	Neurological Disease
AChE/BChE-IN-18 (Compound 4g) is a dual inhibitor of AChE/BChE , with a IC₅₀ value of 0.315 μM for AchE. AChE/BChE-IN-18 is also a CB2R antagonist with a K_i value of 31 nM. AChE/BChE-IN-18 has neuroprotective activity .

HY-157981

AChE-IN-60	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE-IN-60 (compound 6k) is a potant acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 27 nM and 43 nM, respectively. AChE-IN-60 also inhibits monoamine oxidase (MAO)-A and MAO-B with IC₅₀s of 353 nM and 716 nM, respectively .

HY-159081

AChE/BChE-IN-20	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-20 (compound 3m) is an acetylcholinesterase (AChE, IC₅₀=34.81 µM) and butylcholinesterase (BChE, IC₅₀=20.66 µM) inhibitor, which has been demonstrated to have affinity for key enzyme pockets and favorable interaction profiles by molecular docking and kinetic simulations, and can be used in the study of Alzheimer's disease .

HY-146664

AChE/BChE-IN-4	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-4 (BMC-3) is a dual *AChE* and *BChE* inhibitor with IC₅₀ values of 792 nM and 2.2 nM against human AChE (hAChE) and human BChE (hBChE), respectively. AChE/BChE-IN-4 can cross the BBB .

HY-146665

AChE/BChE-IN-5	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-5 (BMC-16) is a dual *AChE* and *BChE* inhibitor with IC₅₀ values of 266 nM and 10.6 nM against human AChE (hAChE) and human BChE (hBChE), respectively. AChE/BChE-IN-5 can cross the BBB .

HY-161508

AChE/BChE-IN-19	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-19 (Compound 12) is a nicotinic hydrazide derivative. AChE/BChE-IN-19 is a inhibitor of *AChE* (IC₅₀ = 21.45 nM) and *BChE* (IC₅₀ =18.42 nM). AChE/BChE-IN-19 can be used in Alzheimer's disease research .

HY-N10701

AChE/BChE-IN-11	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-11 (compound 1) is a potent is a dual *AChE* and *BChE* inhibitor with IC₅₀ values of 70 and 71 μM for AChE and BChE, respectively. AChE/BChE-IN-11 is a natural product that could be isolated from the leaf of artichoke . AChE/BChE-IN-11 can be used in research of Alzheimer’s disease (AD) research .

HY-149484

AChE/BChE-IN-15	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-15 (Compound 6d) is an *AChE/BChE* inhibitor, with IC₅₀s of 20 nM and 220 nM respectively. AChE/BChE-IN-15 binds to both catalytic anionic site (CAS) and peripheral anionic site (PAS) in the active sites of AChE and BChE. AChE/BChE-IN-15 can be used for research of Alzheimer’s disease .

HY-144753

AChE/BChE-IN-2	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-2 (Compound 13b) is a potent inhibitor of *AChE/BChE* (AChE IC50 = 0.96 ± 0.14 µM, BChE IC50 = 1.23 ± 0.23 µM). AChE/BChE-IN-2 has the potential for the research of AD diseases .

HY-146668

AChE/BChE-IN-8	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-8 (Compound 5a) is an uncompetitive *AChE* and mixed *BChE* inhibitor with K_i values of 0.788 μM and 2.364 μM against Electrophorus electricus AChE (EeAChE) and *equine BChE* (eqBChE)*, respectively. AChE/BChE*-IN-8 can cross the BBB and has low cytotoxicity .

HY-159880

AChE/BChE-IN-24	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-24 (compound 5k) is a neuroprotective agent through cholinesterase inhibition. AChE/BChE-IN-24 inhibits *AChE* and *BChE* with IC₅₀ values of 16.38 μM and 10.44 μM, respectively .

HY-151368

AChE/BChE-IN-10	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-10 (Compound 7b) is a potent dual *AChE* and *BChE* inhibitor with IC₅₀ values of 0.176, and 0.47 μM, respectively. AChE/BChE-IN-10 shows good blood brain barrier permeability. AChE/BChE-IN-10 can inhibit Aβ-aggregation and be used in Alzheimer’s disease (AD) research .

HY-159898

AChE/BChE-IN-23	Cholinesterase (ChE) Amyloid-β Tau Protein NOD-like Receptor (NLR) Reactive Oxygen Species Mitochondrial Metabolism	Neurological Disease
AChE/BChE-IN-23 (Compound 6e) is an *AChE/BChE* inhibitor (IC₅₀: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model .

HY-146663

AChE/BChE-IN-3	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-3 (BMC-1) is a dual *AChE* and *BChE* inhibitor with IC₅₀ values of 6.08 μM and 0.383 μM against electric eel AChE (elAChE) and equine serum BChE (eqBChE), respectively .

HY-146663A

AChE/BChE-IN-3 hydrochloride	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-3 (BMC-1) hydrochloride is a dual *AChE* and *BChE* inhibitor with IC₅₀ values of 6.08 μM and 0.383 μM against electric eel AChE (elAChE) and equine serum BChE (eqBChE), respectively .

HY-152114

AChE/BChE/MAO-B-IN-4	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
AChE/BChE/MAO-B-IN-4, an indan-1-one derivative, is a potent MAO-B inhibitor with an IC₅₀ of 0.0393 μM for human MAO-B. AChE/BChE/MAO-B-IN-4 is a potent *AChE* and *BChE* enzyme inhibitor, with IC₅₀s of 0.0458 μM and 0.075 μM for human AChE and BChE enzyme, respectively. AChE/BChE/MAO-B-IN-4 shows significant antioxidant activity and prevent β-amyloid plaque aggregation. AChE/BChE/MAO-B-IN-4 has the potential for Alzheimer's disease (AD) research .

HY-152113

AChE/BChE/MAO-B-IN-3	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
AChE/BChE/MAO-B-IN-3, an indan-1-one derivative, is a potent MAO-B inhibitor with an IC₅₀ of 0.0359 μM for human MAO-B. AChE/BChE/MAO-B-IN-3 is a potent *AChE* and *BChE* enzyme inhibitor, with IC₅₀s of 0.0473 μM and 0.0782 μM for human AChE and BChE enzyme, respectively. AChE/BChE/MAO-B-IN-3 shows significant antioxidant activity and has the potential for Alzheimer's disease (AD) research .

HY-146315

AChE/BChE-IN-6	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BChE-IN-6 (compound 22) is a potent dual *AChE/BChE* inhibitor with IC₅₀ values of 0.809 µM, 2.248 µM and > 100 µM for hBChE, hAChE and hMAO-B, respectively. AChE/BChE-IN-6 penetrates the blood-brain barrier (BBB). AChE/BChE-IN-6 can be used for Alzheimer’s disease (AD) research .

HY-155708

AChE/BChE-IN-13	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-13 (compound 5j) is a potent dual inhibitor of *AChE* and *BChE* with IC₅₀s of 20.89 and 17.37 μM, respectively. AChE/BChE-IN-13 can be used in Alzheimer’s disease (AD) research .

HY-146399

AChE/BChE-IN-9	Cholinesterase (ChE) ROS Kinase	Neurological Disease
AChE/BChE-IN-9 (Compound 7a) is a potent, orally active *AChE* and *BChE* inhibitor with IC₅₀ values of 5.74 μM and 14.05 μM against hAChE and eqBChE, respectively. AChE/BChE-IN-9 is also an efficacious antioxidant with an IC₅₀ of 57.35 μM. AChE/BChE-IN-9 is able to chelate iron and modulates aggregation of amyloid β_{1-42. AChE-IN-16 can cross the BBB} .

HY-161150

AChE/BChE-IN-17	Cholinesterase (ChE) Glucosidase	Neurological Disease Metabolic Disease
AChE/BChE-IN-17 (compound 8m) is a potent and non-competitiveAChE and *BChE* inhibitor, with IC₅₀ values of 125.06 nM and 119.68 nM, respectively. AChE/BChE-IN-17 also inhibits α-glucosidase, with an IC₅₀ of 41050 nM .

HY-152112

AChE/BChE/MAO-B-IN-2	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
AChE/BChE/MAO-B-IN-2 is a potent *AChE, BChE, and MAO-B* enzymes inhibitor with IC₅₀ values of 48.2 nM, 83.9 nM, and 31.2 nM, respectively. AChE/BChE/MAO-B-IN-2 has significant antioxidant activity, and can be used for Parkinson’s disease research .

HY-149211

AChE/BChE-IN-12	Cholinesterase (ChE) Beta-secretase Amyloid-β	Neurological Disease
AChE/BChE-IN-12 (compound 10b), a 3,5-dimethoxy analogue, is a potent *AChE, BChE, and β-secretase-1 (BACE-1)* inhibitor, with IC₅₀ values of 2.57, 3.26, and 10.65 μM, respectively. AChE/BChE-IN-12 crosses the blood-brain barrier via passive diffusion and inhibits the self-aggregation of amyloid-β monomers. AChE/BChE-IN-12 can be used for Alzheimer’s disease (AD) research .

HY-131971

AChE/BChE-IN-1	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-1 is a potent and brain-penetrant dual inhibitor of Acetylcholinesterase and Butyrylcholinesterase, with IC₅₀s of 1.06 and 7.3 nM for hAChE and hBChE, respectively. AChE/BChE-IN-1 also has antioxidant activity. AChE/BChE-IN-1 can be used for the research of Alzheimer’s disease .

HY-169205

AChE/BChE-IN-22	Cholinesterase (ChE)	Cancer
AChE/BChE-IN-22 (compund 7) competitively inhibits both *AChE* and BChE enzymes, with values of 28.18±2.51 and 41.74±3.18μM, respectively .

HY-N8764

Decaffeoylacteoside Decaffeoylverbascoside; Verbasoside	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease Cancer
Decaffeoylacteoside is an inhibitor of *AChE/BChE/LOX* with moderate activity .

HY-146312

AChE/BChE/MAO-B-IN-1	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BChE/MAO-B-IN-1 (Compound 10) is a reversible and non-time-dependent *AChE, BChE* and MAO-B inhibitor with IC₅₀ values of 7.31, 0.56 and 26.1 μM for hAChE, hBChE and hMAO-B, respectively. AChE/BChE/MAO-B-IN-1 can cross the BBB and shows neuroprotective effects without cytotoxicity .

HY-157520

BChE-IN-25	Cholinesterase (ChE)	Others
BChE-IN-25 (compound 4I) is a selective *BChE* inhibitor (IC₅₀: 3.77μM), which is 22 times more selective for BChE than AChE .

HY-147659

AChE/BChE/BACE-1-IN-2	Cholinesterase (ChE) Beta-secretase ROS Kinase	Neurological Disease
AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of *AChE, BChE, and BACE-1* with IC₅₀ values of 0.069, 0.127 and 0.097 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-2 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-2 has remarkable antioxidant potential .

HY-147658

AChE/BChE/BACE-1-IN-1	Cholinesterase (ChE) Beta-secretase ROS Kinase	Neurological Disease
AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of *AChE, BChE, and BACE-1* with IC₅₀ values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-1 has remarkable antioxidant potential .

HY-162338

BChE-IN-29	Cholinesterase (ChE)	Neurological Disease
BChE-IN-29 (Compound 27a) is a *BChE* inhibitor (IC₅₀: 0.078 μM and 0.74 μM for BChE and AChE respectively). BChE-IN-29 has anti-inflammatory activity and can be used for research of AD .

HY-157982

BChE-IN-28	Cholinesterase (ChE)	Neurological Disease
BChE-IN-28 (compound 6J) is a selective butyrylcholinesterase (BChE) inhibitor with an IC₅₀ of 8 nM and a K_i of 12.16 nM. BChE-IN-28 shows the lower inhibition against AChE, MAO-A and MAO-B .

HY-144689

BChE-IN-3	Cholinesterase (ChE)	Neurological Disease
BChE-IN-3 (compound 45a) is a potent, selective, time-dependent and pseudoirreversible *BChE* inhibitor, with an IC₅₀ of 56.9 nM. BChE-IN-3 also shows marginal and reversible (not time-dependent) inhibition of *AChE* .

HY-146313

BChE-IN-7	Cholinesterase (ChE)	Neurological Disease
BChE-IN-7 (compound 13) is a potent, selective, BBB-penetrated and reversible *AChE* and *BChE* inhibitor, with an IC₅₀ of 0.06 μM (BChE). BChE-IN-7 can protect neuronal-like cells from toxic Aβ-species .

HY-122140

ACG548B	Cholinesterase (ChE)	Neurological Disease
ACG548B (compound 24) is a potent inhibitor of acetyl- and butyrylcholinesterase (AChE and *BChE) with IC₅₀s of 1.78 and 0.496 μM, respectively. ACG548B has higher AChE* affinity and selectivity over *BChE* and ChoK (choline kinase) .

HY-155713

AChE-IN-34	Cholinesterase (ChE)	Neurological Disease
AChE-IN-34 (compound 5l) is a potent and selective *AChE* inhibitor with an IC₅₀ value of 3.98 µM with no significant inhibition against BChE. AChE-IN-34 inhibits AChE with a Ki of 0.044 μM in a mixed mode (Acetylthiocholine substrate; 0.1-1 mM) .

HY-155140

BChE-IN-17	Cholinesterase (ChE)	Neurological Disease
BChE-IN-17 (compound 6n) is a potent and selective *BChE* inhibitor with IC₅₀s of 10.5 nM and 32.5 nM for eqBChE and hBChE, respectively. BChE-IN-17 shows over 1000-fold selectivity to BChE against AChE. BChE-IN-17 shows low neurotoxicity and moderate neuroprotective effects .

HY-W324391

Coumarin 106 Coumarin 478	Cholinesterase (ChE)	Neurological Disease
Coumarin 106 (Coumarin 478) is a dipolar laser dye. Coumarin 106 is an inhibitor of AChE and BChE. Coumarin 106 displays mixed-type AChE inhibition with a pIC₅₀=4.97 and K_i=2.36 μM. Coumarin 106 inhibits BChE with slightly lower potency (pIC₅₀=4.56) .

HY-168031

AChE/BChE-IN-21	Histamine Receptor Calcium Channel Cholinesterase (ChE) Reactive Oxygen Species Amyloid-β	Neurological Disease
AChE/BChE-IN-21 is a histamine H₃ receptor antagonist, calcium channel blocker, and acetylcholinesterase inhibitor. AChE/BChE-IN-21 exhibits neuroprotective activity against H₂O₂ and Aβ_1-40, and can restore cognitive function in AD mice .

HY-161156

BChE-IN-26	Cholinesterase (ChE)	Neurological Disease Cancer
BChE-IN-26 (Compound 7b) is a selective *AChE* and *BChE* inhibitor with K_i value of 35 μM and 1.6 μM. BChE-IN-26 has cytotoxicity to human neuroblastoma (SH-SY5Y) cell line. BChE-IN-26 can be used for the research of Alzheimer’s disease .

HY-B2244

Tacrine hydrochloride (hydrate) 5 Publications Verification	Cholinesterase (ChE)	Neurological Disease
Tacrine hydrochloride (hydrate) is an inhibitor of both acetyl (AChE) and butyryl-cholinestrase (BChE) with IC₅₀s of 31 nM and 25.6 nM, respectively.

HY-156754

3β-Hydroxy-lup-20(29)-en-16-one	Cholinesterase (ChE)	Neurological Disease
3β-Hydroxy-lup-20(29)-en-16-one (compound 9) is a dual inhibitor of AChE and BChE, with selectivity for BChE (IC₅₀: 28.9 μM) .

HY-135006A

Octahydroaminoacridine	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine, a Tacrine analogue, is an acetylcholinesterse (AChE) and butyrylcholinesterase (BChE) inhibitor. Octahydroaminoacridine can be used for Alzheimer's disease (AD) research .

HY-157087

AChE/MAO-B-IN-4	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/MAO-B-IN-4 (compound 4a) is a selective dual *AChE* and MAO-B inhibitor. AChE/MAO-B-IN-4 shows no significant inhibition activity against BChE and h-MAO-A. AChE/MAO-B-IN-4 can be used for the Alzheimer’s disease (AD) research .

HY-135006

Octahydroaminoacridine succinate	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine succinate, a Tacrine analogue, is an acetylcholinesterse (AChE) and butyrylcholinesterase (BChE) inhibitor. Octahydroaminoacridine succinate can be used for Alzheimer's disease (AD) research .

HY-N10917

Xanthohumol I	Cholinesterase (ChE)	Infection Cancer
Xanthohumol I, a chalkone, is a derivative of Xanthohumol (HY-N1067). Xanthohumol is a Cholinesterase (ChE) inhibitor, which inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) wih IC₅₀s of 71.34 μM and 32.67 μM, respectively. The hydroxy compound of Xanthohumol (3-hydroxy-xanthohumol), also shoes inhibitory effect on *AChE* and *BChE* with IC₅₀s of 51.25 μM and 63.07 μM .

HY-149300

SB-1436	Cholinesterase (ChE)	Neurological Disease
SB-1436 is an Cholinesterase (ChE) inhibitor, inhibits acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and recombinant human acetylcholinesterase (rHuAChE) with IC₅₀s of 0.176, 0.37 and 0.08 μM, respectively. SB-1436 inhibits AChE and BChE in a non-competitive manner with K_is of 0.046 and 0.115 μM, respectively. SB-1436 significantly stops the self-aggregation of Aβ, and can be used for neurological disease research .

HY-107922

Ethopropazine hydrochloride Isothazine hydrochloride; Lysivane hydrochloride; Parsidol hydrochloride	Cholinesterase (ChE)	Neurological Disease
Ethopropazine (Isothazine) hydrochloride is a potent, selective *BChE* inhibitor and a poor *AChE* inhibitor. Ethopropazine hydrochloride is a phenothiazine compound with anticholinergic properties. Ethopropazine hydrochloride can be used for the research of Parkinson’s disease .

HY-157437

AChE/BChE-IN-16	Cholinesterase (ChE) Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
AChE/BChE-IN-16 (compound C7) is a potent cholinesterase (ChE) inhibitor with IC₅₀s of 30 nM and 48 nM for human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE), respectively. AChE/BChE-IN-16 exhibits a remarkable capacity to safeguard PC12 cells against H₂O₂-induced apoptosis and effectively suppresses the production of reactive oxygen species (ROS) .

HY-163909

AChE-IN-72	Cholinesterase (ChE)	Neurological Disease
AChE-IN-72 (Compound 13a) is an inhibitor for acetylcholinesterase (AChE) with an IC₅₀ of 0.59 μM. AChE-IN-72 inhibits *BChE* with an IC₅₀ of 5.02 μM. AChE-IN-72 exhibits radical scavenging with IC₅₀ of 5.88 μM. AChE-IN-72 exhibits iron-chelating property, inhibits Aβ1−42 aggregation, and inhibits NLRP3 inflammasome activation. AChE-IN-72 ameliorates memory impairment in Betaine (HY-B0710)-induced AD mouse model. AChE-IN-72 is blood-brain barrier (BBB) penetrable .

Cat. No.	Product Name	Type

HY-W324391

Coumarin 106 Coumarin 478	Dyes
Coumarin 106 (Coumarin 478) is a dipolar laser dye. Coumarin 106 is an inhibitor of AChE and BChE. Coumarin 106 displays mixed-type AChE inhibition with a pIC₅₀=4.97 and K_i=2.36 μM. Coumarin 106 inhibits BChE with slightly lower potency (pIC₅₀=4.56) .

HY-103373

PE154	Fluorescent Dyes/Probes
PE154 (Compound 13) is a potent fluorescent inhibitor of human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) (IC₅₀s=280 pM and 16 nM, respectively) . PE154 can label β-amyloid plaques in histochemical analysis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2284

Sophoflavescenol	Flavonols Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Plants Sophora flavescens Aiton Disease Research Fields Cancer	Cholinesterase (ChE) Beta-secretase Phosphodiesterase (PDE)
Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC₅₀ of 0.013 μM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC₅₀s of 0.30 µM, 0.17 µM, 17.89 µg/mL, 10.98 µM, 8.37 µM and 8.21 µM, respectively.

HY-107569

Garcinol 1 Publications Verification	Structural Classification Classification of Application Fields Guttiferae Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Garcinia indica	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 µM and 7.39 µM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀ = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

HY-N10701

AChE/BChE-IN-11	Structural Classification Oleaceae Syringa oblata Lindl. Source classification Plants Saccharides Monosaccharides	Cholinesterase (ChE)
AChE/BChE-IN-11 (compound 1) is a potent is a dual *AChE* and *BChE* inhibitor with IC₅₀ values of 70 and 71 μM for AChE and BChE, respectively. AChE/BChE-IN-11 is a natural product that could be isolated from the leaf of artichoke . AChE/BChE-IN-11 can be used in research of Alzheimer’s disease (AD) research .

HY-N8764

Decaffeoylacteoside Decaffeoylverbascoside; Verbasoside	Structural Classification Labiatae Source classification Phenols Polyphenols Plants Ambrosia hispida	Monoamine Oxidase Cholinesterase (ChE)
Decaffeoylacteoside is an inhibitor of *AChE/BChE/LOX* with moderate activity .

HY-N10917

Xanthohumol I	Structural Classification Humulus lupulus L. Source classification Phenols Polyphenols Plants Moraceae	Cholinesterase (ChE)
Xanthohumol I, a chalkone, is a derivative of Xanthohumol (HY-N1067). Xanthohumol is a Cholinesterase (ChE) inhibitor, which inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) wih IC₅₀s of 71.34 μM and 32.67 μM, respectively. The hydroxy compound of Xanthohumol (3-hydroxy-xanthohumol), also shoes inhibitory effect on *AChE* and *BChE* with IC₅₀s of 51.25 μM and 63.07 μM .

HY-108048

Desoxypeganine Deoxypeganine; Deoxyvasicine	Structural Classification Alkaloids Peganum nigellastrum Bunge Zygophyllaceae Source classification Quinoline Alkaloids Plants	Cholinesterase (ChE) Monoamine Oxidase
Desoxypeganine (Deoxypeganine), an alkaloid, is a potent and orally active cholinesterase (BChE and *AChE) and selective MAO-A* inhibitor, with IC₅₀ values of 2, 17, and 2 μM, respectively. Desoxypeganine can be used for alcohol abuse research .

HY-127087

Isogarcinol Cambogin	Structural Classification Source classification Guttiferae Phenols Polyphenols Plants Symphonia globulifera L.f.	Cholinesterase (ChE) Parasite
Isogarcinol (Cambogin) is a potent *AChE* and *BChE* inhibitor, with IC₅₀ values of 1.13 and 8.30 μM, respectively. Isogarcinol also shows leishmanicidal activity, with an IC₅₀ of 0.33 μM against L. donovani .

HY-N12075

Dehydrodiscretamine chloride	Structural Classification Alkaloids Piperidine Alkaloids Nandina domestica Thunb. Fissistigma polyanthum (Hook. f. et Thoms.) Merr. Source classification Plants Annonaceae Berberidaceae	Cholinesterase (ChE)
Dehydrodiscretamine chloride is a dual inhibitor of *AChE* and *BChE* with IC₅₀s of 17.8 and 118.8 μM, respectively. Dehydrodiscretamine chloride has antioxidant activity. Dehydrodiscretamine chloride can be used in study Alzheimer’s disease .

HY-N12581

Kuwanon U	Structural Classification Flavonoids Flavonones Source classification Morus alba L. Plants Moraceae	Cholinesterase (ChE)
Kuwanon U is a potent cholinesterase inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

HY-N10429

Geissoschizoline (+)-Geissoschizoline	Alkaloids other families Pyrrole Alkaloids Classification of Application Fields Neurological Disease Source classification Pteris wallichiana Agardh Plants Disease Research Fields Inflammation/Immunology Indole Alkaloids	Cholinesterase (ChE)
Geissoschizoline ((+)-Geissoschizoline) is a potent inhibitor of human *AChE/BChE, with IC₅₀s* of 20.40 µM and 10.21 µM, respectively. Geissoschizoline emerges as a possible multi-target prototype that can be very useful in studies of preventing neurodegeneration and restoring neurotransmission. Geissoschizoline aiso is a potent anti-inflammatory agent .

HY-N0226

Epiberberine	Alkaloids Source classification Ranunculaceae Coptis chinensis Franch. Plants Isoquinoline Alkaloids	Cholinesterase (ChE) Beta-secretase
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent *AChE* and *BChE* inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease . Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-N0226A

Epiberberine chloride 4 Publications Verification	Alkaloids Structural Classification Neurological Disease Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Source classification Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent *AChE* and *BChE* inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease . Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

Cat. No.	Product Name	Chemical Structure

HY-17368S1

(Rac)-Rivastigmine-d6

(Rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].

HY-W654336

(S)-Rivastigmine-d4

(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368S2

Rivastigmine-d3 hydrochloride

Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W654335

Rivastigmine-d4 tartrate

Rivastigmine-d₄ (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks